Watertown, Massachusetts-based Disc has agreed with the FDA that it will use average monthly time in sunlight during the last ...

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for ...

The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...

Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...

NHS England has started a pilot trial of an iPhone app and device combination that could be used by nursing staff to speed up ...

Lawyers for AstraZeneca, Bristol-Myers Squibb, and Johnson & Johnson argued at a panel hearing in Philadelphia late last week ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated ...

Generic drugmaker Accord Healthcare has announced a £50 million ($65 million) investment in the UK that will include the ...

The fine of €462.6 million ($503 million) is believed to be the largest imposed on a pharma company for breaking antitrust ...

As the race to deliver personalised engagement at scale heats up, artificial intelligence (AI) has become the critical ...

Islet cell transplantation is used in type 1 diabetes to replace the insulin-producing beta cells that are destroyed by the ...

Novartis has exclusive rights to MRT-6160 and follow-up VAV1 degraders and will be responsible for development activities ...